Market closed
Avid Bioservices/$CDMO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Avid Bioservices
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Ticker
$CDMO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
-
Website
Avid Bioservices Metrics
BasicAdvanced
$787M
Market cap
-
P/E ratio
-$2.39
EPS
1.41
Beta
-
Dividend rate
Price and volume
Market cap
$787M
Beta
1.41
52-week high
$12.30
52-week low
$4.66
Average daily volume
3.1M
Financial strength
Current ratio
1.301
Quick ratio
0.881
Long term debt to equity
455.457
Total debt to equity
462.016
Interest coverage (TTM)
-2.30%
Management effectiveness
Return on assets (TTM)
-3.27%
Return on equity (TTM)
-133.29%
Valuation
Price to revenue (TTM)
5.202
Price to book
17.57
Price to tangible book (TTM)
17.57
Price to free cash flow (TTM)
-80.835
Growth
Revenue change (TTM)
6.75%
Earnings per share change (TTM)
1,128.92%
3-year revenue growth (CAGR)
12.28%
3-year earnings per share growth (CAGR)
160.01%
What the Analysts think about Avid Bioservices
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avid Bioservices stock.
Avid Bioservices Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Avid Bioservices Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Avid Bioservices News
AllArticlesVideos
The Schall Law Firm Urges Stockholder Participation In An Inquiry Into Avid Bioservices Inc For Possible Securities Fraud
Accesswire·10 hours ago
Avid Bioservices, Inc. Is Being Investigated For Securities Related Infractions And Affected Investors Are Invited To Contact The Schall Law Firm
Accesswire·2 days ago
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avid Bioservices stock?
Avid Bioservices (CDMO) has a market cap of $787M as of December 14, 2024.
What is the P/E ratio for Avid Bioservices stock?
The price to earnings (P/E) ratio for Avid Bioservices (CDMO) stock is 0 as of December 14, 2024.
Does Avid Bioservices stock pay dividends?
No, Avid Bioservices (CDMO) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Avid Bioservices dividend payment date?
Avid Bioservices (CDMO) stock does not pay dividends to its shareholders.
What is the beta indicator for Avid Bioservices?
Avid Bioservices (CDMO) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.